TAX2, our lead program
PHASE 1/2a ONGOINGTAX2 (AP-01) is a first-in-class cyclic peptide that binds TSP-1 to selectively disrupt its interaction with CD47, with the aim of restoring anti-tumor immunity.
Its development is supported by a comprehensive nonclinical package and independent preclinical findings published in Nature Immunology.
Beyond TAX2, our pipeline includes preclinical programs in oncology and other areas.
Extracellular matrix targeting technology
We develop peptides to modulate interactions between extracellular proteins and cell-surface receptors, opening new therapeutic approaches in oncology.
Designing peptides for challenging extracellular targets
Our proprietary platform integrates computational design with peptide engineering and experimental validation.
Computational design
We characterize challenging extracellular targets using AI-assisted molecular modeling and molecular dynamics simulations.
Peptide engineering and validation
We engineer and test peptide candidates to optimize biological activity, stability and manufacturability.
The expertise to advance peptide therapeutics
Our team brings together expertise in extracellular biology, peptide discovery, nonclinical development, manufacturing and clinical development.
Our programs are supported by scientific, clinical and strategic advisors.
Meet our team
- Albin JEANNECEO / CSO
- Abderrahim LACHGARBoard Member
- Stéphane DEDIEUChair of the Scientific and Clinical Advisory Board
Latest news
Stay informed about our scientific advances, clinical progress, and company updates.
